





CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucricitbant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks

Henry H. Li¹, Henriette Farkas², Anete S. Grumach³, Michihiro Hide⁴, Joshua S. Jacobs⁵, Lucy Leeman⁶, Philip H. Li⁷, Ramón Lleonart⁸, Hilary J. Longhurst⁹, William R. Lumry¹⁰, Markus Magerl^{11,12}, Inmaculada Martinez-Saguer¹³, Jonny Peter¹⁴, Sinisa Savic¹⁵, Marcin Stobiecki¹⁶, Raffi Tachdjian¹⁷, Anna Valerjeva¹⁸, H. James Wedner¹⁹, Andrea Zanichelli^{20,21}, Ricardo Zwiener²², Christoph Cirillo²³, Rafael Crabbé²³, Li Zhu²⁴, Ulrich Freudensprung²³, Joan Mendivil²³, Ming Yu²⁴, Peng Lu²⁴, Emel Ayyören-Pürsün²⁵

¹Institute for Asthma and Allergy, Chevy Chase, MD, USA; ²Semmelweis University, Department of Internal Medicine and Haematology, Hungarian Angioedema Center of Reference and Excellence, Budapest, Hungary; ³Centro Universitario FMABC, Clinical Immunology, Sao Paulo, Brazil; ⁴Hiroshima University and Hiroshima City Hospital Organization, Department of Dermatology, Hiroshima, Japan; ⁵Allergy and Asthma Clinical Research, Walnut Creek, CA, USA; ⁶University Hospitals Plymouth NHS Trust, the Peninsula Immunology and Allergy Service, Plymouth, UK; ⁷Queen Mary Hospital, University of Hong Kong, Division of Rheumatology and Clinical Immunology, Department of Medicine, Hong Kong; ⁸Bellvitge University Hospital, L'Hospitalet de Llobregat, Allergy Service, Barcelona, Spain; ⁹School of Medicine, University of Auckland and Department of Immunology, Auckland City Hospital and LabPlus, Auckland, New Zealand; ¹⁰Allergy and Asthma Research Associates Research Center, Dallas, TX, USA; ¹¹Charité-Universitätsmedizin Berlin, Institute of Allergology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; ¹²Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin, Germany; ¹³HZRM Hämophilie Zentrum Rhein Main, Diagnostik, Therapie und Erforschung von Gerinnungsstörungen, Immundefekten und HAE, Frankfurt, Germany; ¹⁴Groote Schuur Hospital, Division of Allergy and Clinical Immunology, University of Cape Town and Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa; ¹⁵University of Leeds, the Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK; ¹⁶Jagiellonian University Medical College, Department of Clinical and Environmental Allergology, Krakow, Poland; ¹⁷University of California at Los Angeles, Division of Allergy, Immunology, and Rheumatology, Los Angeles, CA, USA; ¹⁸Medical University of Sofia, Department of Allergology, Sofia, Bulgaria; ¹⁹Washington University School of Medicine, Division of Allergy and Immunology, Department of Medicine, St Louis, MO, USA; ²⁰Università degli Studi di Milano, Dipartimento di Scienze Biomediche per la Salute, Milan, Italy; ²¹I.R.C.C.S., Policlinico San Donato, Centro Angioedema, UO Medicina, Milan, Italy; ²²Hospital Universitario Austral, Servicio de Alergia e Inmunología, Buenos Aires, Argentina; ²³Pharvaris GmbH, Zug, Switzerland; ²⁴Pharvaris Inc., Lexington, MA, USA; ²⁵University Hospital Frankfurt, Goethe University Frankfurt, Department for Children and Adolescents, Frankfurt, Germany

Key takeaways

- CHAPTER-3 is an ongoing, global, Phase 3 study designed to evaluate the efficacy and safety of once-daily, oral deucricitbant extended-release (XR) tablet for prophylaxis of attacks in adolescents and adults with hereditary angioedema (HAE).
- Results from the Phase 2 CHAPTER-1 study support the CHAPTER-3 study design

Deucricitbant	Primary efficacy endpoint	Safety endpoints	Patient-reported outcomes
 Deucricitbant XR once-daily tablet	 Time-normalized number of investigator-confirmed HAE attacks during the 24-week treatment period	 TEAEs, clinical laboratory tests, vital signs, and ECG parameters	 Health-related quality of life, disease control, work productivity and activity impairment, and treatment satisfaction

ECG, electrocardiogram; HAE, hereditary angioedema; TEAE, treatment-emergent adverse event; XR, extended-release.

Background

- Hereditary angioedema (HAE):** a rare genetic condition caused by excess bradykinin production and characterized by painful, often disabling, swelling attacks affecting multiple locations in the body.¹⁻³
- Unmet need:** additional prophylactic treatments offering injectable-like efficacy, a well-tolerated profile, and ease of administration.^{4,7}
- Deucricitbant:** deucricitbant is a selective, orally administered antagonist of the bradykinin B2 receptor under development for prophylactic and on-demand treatment of HAE attacks.⁸⁻¹⁸

Objective

To evaluate the efficacy and safety of once-daily, oral deucricitbant XR tablet for prophylaxis of attacks in adolescents and adults with HAE in CHAPTER-3 (NCT06669754), an ongoing, global, Phase 3 study.


Previous studies

CHAPTER-1

- In the placebo-controlled, Phase 2 trial (NCT05047185), deucricitbant significantly reduced occurrence of attacks, induced clinically meaningful improvement in disease control and in health-related quality of life, and was generally well tolerated.^{14,15}
- Attack rate was significantly reduced with deucricitbant in the randomized controlled trial (RCT) and remained low over long-term treatment in the open-label extension (OLE).
- The immediate-release (IR) capsule was dosed twice per day as a proof-of-concept for the once-daily deucricitbant XR tablet (intended formulation for prophylactic HAE treatment).
- CHAPTER-1 results supported further development of deucricitbant as a potential prophylactic treatment for HAE.¹⁵

Previous studies

Figure 1. Reduced attack rate by week 1 in the CHAPTER-1 RCT remained low in the OLE




IR, immediate-release; OLE, open-label extension; RCT, randomized controlled trial; SEM, standard error of the mean. n = number of patients analyzed at each timepoint. *Based on time normalized number of attacks per 4 weeks. ¹1 month = 4 weeks. ²Deucricitbant IR capsule, 10 mg twice daily. ³Deucricitbant IR capsule, 20 mg twice daily.

Phase 1 studies with deucricitbant XR tablet

- In Phase 1 studies, deucricitbant XR tablet (40 mg):
 - Allowed for controlled release and absorption of deucricitbant in the small intestine and colon.¹⁸
 - Sustained mean concentrations in circulation above threshold levels of therapeutic exposure from ~1.5 to ≥24 hours post-dose.^{18,20} Effective concentration estimated to provide 85% maximal response (EC_{85}) is 13.8 ng/mL.^{18,19}
 - Showed more sustained exposure over time compared with twice-daily IR capsule (2 x 20 mg) used in proof-of-concept Phase 2 CHAPTER-1 study.^{18,20}
- Maintenance of exposure through 24 hours supports once-daily dosing with XR tablet for prophylactic treatment.

Figure 2. Deucricitbant XR tablet maintains exposure above threshold level of therapeutic exposure for ≥24 hours




EC_{85} , concentration estimated to provide 85% maximal response; IR, immediate-release; SD, standard deviation; XR, extended-release. ¹Single oral dose of 2 x 20 mg deucricitbant IR capsule.

CHAPTER-3 study overview

- CHAPTER-3 (NCT06669754):** an ongoing Phase 3, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of orally administered deucricitbant XR tablet once daily for prophylaxis of HAE attacks in adolescents and adults.
- Target enrollment:** 81 adolescents and adults living with HAE.
- Randomization:** 2:1 to receive deucricitbant XR tablet 40 mg or matching placebo once daily for 24 weeks. Stratified according to:
 - age group (≥12 to <18 years, ≥18 years) and
 - baseline HAE attack rate (1 to <2 attacks per 4 weeks, ≥2 attacks per 4 weeks).
- Extension studies:** participants who complete the 24-week treatment period can elect to continue deucricitbant XR tablet treatment in the CHAPTER-4 (NCT06679881) open-label extension.¹⁷

Figure 3. CHAPTER-3 and CHAPTER-4 study design



R, randomization; XR, extended-release.

Participants

Table 1. CHAPTER-3 key inclusion and exclusion criteria

Key inclusion criteria include	Key exclusion criteria include
<ul style="list-style-type: none"> Aged ≥12 years Diagnosed with HAE History of ≥3 HAE attacks within the 3 consecutive months prior to screening visit Access and ability to use standard-of-care on-demand treatment to manage HAE attacks 	<ul style="list-style-type: none"> Participation in any other investigational drug study Received prior HAE prophylactic treatment with deucricitbant Receiving long-term prophylactic therapy for HAE within the specified time-period before screening: <ul style="list-style-type: none"> 2 weeks: C1 inhibitor, berotralstat, or anti-fibrinolytic 4 weeks: Attenuated androgen 5 half-lives: Lanadelumab Pregnant or breastfeeding

HAE, hereditary angioedema.

CHAPTER-3 study overview

- Objectives and endpoints**
- Primary objective:** evaluate efficacy of deucricitbant XR tablet for prevention of angioedema attacks vs placebo.
- Secondary objectives:**
 - evaluate efficacy
 - evaluate safety and tolerability
 - evaluate pharmacokinetics
 - evaluate impact on health-related quality of life

Table 2. Study endpoints in CHAPTER-3

Primary endpoint	Time-normalized (per 4 weeks) number of investigator-confirmed HAE attacks during the 24-week treatment period
Secondary efficacy endpoints	<ul style="list-style-type: none"> Number of attacks treated with on-demand medication Number of "moderate or severe" and "severe" attacks^a Proportion of participants achieving ≥50%, ≥70%, or ≥90% reduction in attack rate relative to baseline and proportion remaining attack free Proportion of time without angioedema symptoms
Patient-reported outcomes	<ul style="list-style-type: none"> Angioedema Quality of Life (AE-QoL) questionnaire Patient Global Assessment of Change (PGA-Change) Angioedema Control Test 4-week version (AECT-4wk) Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9)
Safety	<ul style="list-style-type: none"> TEAEs including serious TEAEs and TEAEs leading to study drug discontinuation Change from baseline in clinical laboratory tests, vital signs, and ECG parameters

ECG, electrocardiogram; HAE, hereditary angioedema; TEAE, treatment-emergent adverse event. ^aModerate attacks defined as an HAE attack that limits/interferes with the participant's ability to attend work/school or participate in family life and social/recreational activities. Severe attack defined as an HAE attack that significantly limits the participant's ability to attend work/school or participate in family life and social/recreational activities.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

References

- Busse PJ, et al. *N Engl J Med*. 2020;382:1136-48.
- Bork K, et al. *Allergy Asthma Clin Immunol*. 2021;17:40.
- Mendivil J, et al. *Orphanet J Rare Dis*. 2021;16:94.
- Bouillet L, et al. *Allergy Asthma Proc*. 2022;43:406-12.
- Covella B, et al. *Future Pharmacol*. 2024;4:41-53.
- Center for Biologics Evaluation and Research. The voice of the patient – hereditary angioedema. US Food and Drug Administration; May 2018. Accessed June 16, 2025. <https://www.fda.gov/media/113509/download>.
- Betschel SD, et al. *J Allergy Clin Immunol Pract*. 2023; 11:2315-25.
- Lesage A, et al. *Front Pharmacol*. 2020;11:916.
- Lesage A, et al. *Int Immunopharmacol*. 2022;105:108523.
- RAPiDe-1. Accessed June 16, 2025. <https://clinicaltrials.gov/study/NCT04618211>.
- RAPiDe-2. Accessed June 16, 2025. <https://www.clinicaltrials.gov/study/NCT05396105>.
- RAPiDe-3. Accessed June 16, 2025. <https://clinicaltrials.gov/study/NCT06343779>.
- Maurer M, et al. Presented at: AAAA; February 24–27, 2023; San Antonio, TX, USA.
- CHAPTER-1. Accessed June 16, 2024. <https://www.clinicaltrials.gov/study/NCT05047185>.
- Ayyören-Pürsün, et al. Presented at: EAACI; May 31–June 3, 2024; Valencia, Spain.
- CHAPTER-3. Accessed June 16, 2025. <https://clinicaltrials.gov/study/NCT06669754>.
- CHAPTER-4. Accessed June 16, 2025. <https://clinicaltrials.gov/study/NCT06679881>.
- Lesage A, et al. Presented at: IDDS; May 22–24, 2024; Otsaka, Japan.
- Groen K, et al. Presented at: ACAAI 2022. November 10–14, 2022; Louisville, KY, USA.
- Zhang Y-Z, et al. Presented at: C11NH Deficiency & Angioedema Workshop; May 29–June 1, 2025; Budapest, Hungary.